Ultragenyx Pharmaceutical

Youtube Subscribe

Open: 48.02 Close: 46.65 Change: -1.37

Are you looking for information about Ultragenyx Pharmaceutical? We programmed an AI to summarize it for you.

The game is changing. There is a new strategy to evaluate Ultragenyx Pharmaceutical fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ultragenyx Pharmaceutical are: Ultragenyx, Pharmaceutical, analysis, Biopharmaceutical, company, RARE, develop, …

Concept Map

Semantic Network

Stock Summary

Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab.

Today's Summary

Biopharmaceutical company Ultragenyx Pharmaceutical ( RARE ) is developing novel products for the treatment of serious rare and ultra-rare genetic diseases. BrainTale plans to use the funding to expand its presence in Europe. Ultragenyx Pharmaceutical ( NASDAQ:RARE – Free Report ) last posted its earnings results on Thursday, May 4th. Ultragenx Pharmaceuticals revenue was up 25.8% on a year-over-year basis. The stock has a market cap of $3.40 billion, a PE ratio of -4.68. The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Ultragenyx Pharmaceutical is an equal opportunity employer.

Today's News

Biopharmaceutical company Ultragenyx Pharmaceutical ( RARE ) is developing novel products for the treatment of serious rare and ultra-rare genetic diseases. BrainTale plans to use the funding to expand its presence in Europe. Ultragenyx Pharmaceutical ( NASDAQ:RARE – Free Report ) last posted its earnings results on Thursday, May 4th. Ultragenx Pharmaceuticals revenue was up 25.8% on a year-over-year basis. The stock has a market cap of $3.40 billion, a PE ratio of -4.68. The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Ultragenyx Pharmaceutical is an equal opportunity employer.

Stock Profile

"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California."

Keywords

Are looking for the most relevant information about Ultragenyx Pharmaceutical? Investor spend a lot of time searching for information to make investment decisions in Ultragenyx Pharmaceutical. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ultragenyx Pharmaceutical are: Ultragenyx, Pharmaceutical, analysis, Biopharmaceutical, company, RARE, develop, and the most common words in the summary are: state, united, pharmaceutical, therapeutic, ultragenyx, job, best, . One of the sentences in the summary was: BrainTale plans to use the funding to expand its presence in Europe. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #pharmaceutical #therapeutic #ultragenyx #job #best.

Read more →

Youtube Subscribe

---